Treatment of BPH With CO2 Serenoa +PEA as Monotherapy or in Combination With Tamsulosin: ProSeRePEA Trial

Inclusion Criteria: * male with age\> 40 years * baseline International Prostate Symptoms Score between 8 and 14 * prostate volume ≤ 60 cc assessed by transrectal ultrasound (TRUS) * maximum flow (Qmax at uroflowmetry) ≤ 15 ml / sec * post voiding residue on extemporaneous ultrasound ≤ 120 ml * Signature of informed consent for participation in the study * ability to understand the conditions of the study and to participate in the study throughout its duration. Exclusion Criteria: * urinary incontinence * overactive bladder * neurological bladder * malignancies in progress and which have undergone treatment in the previous 6 months * local or systemic infections (urinary tract infection, osteomyelitis, sepsis, etc.) * kidney failure * macrohematuria * bladder stones